Iodophenpropit Dihydrobromide | CAS#145196-87-8

MedKoo Cat#: 525348 | Name: Iodophenpropit Dihydrobromide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iodophenpropit Dihydrobromide is a potent and selective H3 antagonist.

Chemical Structure

Iodophenpropit Dihydrobromide

CAS#145196-87-8

Theoretical Analysis

MedKoo Cat#: 525348

Name: Iodophenpropit Dihydrobromide

CAS#: 145196-87-8

Chemical Formula: C15H21Br2IN4S

Exact Mass:

Molecular Weight: 576.13

Elemental Analysis: C, 31.27; H, 3.67; Br, 27.74; I, 22.03; N, 9.72; S, 5.56

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
50mg	USD 1,100.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Iodophenpropit Dihydrobromide

IUPAC/Chemical Name

3-(1H-Imidazol-5-yl)propyl N"-[2-(4-iodophenyl)ethyl]carbamimidothioate dihydrobromide

InChi Key

BOSOGNBLIWPCMS-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H19IN4S.2BrH/c16-13-5-3-12(4-6-13)7-8-19-15(17)21-9-1-2-14-10-18-11-20-14;;/h3-6,10-11H,1-2,7-9H2,(H2,17,19)(H,18,20);2*1H

SMILES Code

N=C(SCCCC1=CN=CN1)NCCC2=CC=C(I)C=C2.[H]Br.[H]Br

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Iodophenpropit dihydrobromide is a potent and selective histamine H3 receptor antagonist. The binding of [125I]Iodophenpropit is selective, saturable, readily reversible, and of high affinity (KD 0.32 nM).

In vitro activity:

IPP proved to be a potent competitive H3 receptor antagonist as measured against (R)-alpha-methylhistamine-induced inhibition of electrically-evoked contractions of the guinea-pig jejunum (pA2 = 9.12 +/- 0.06, Schild slope: 1.0 +/- 0.1, n = 8). Reference: Br J Pharmacol. 1995 Oct;116(4):2315-21. https://pubmed.ncbi.nlm.nih.gov/8564266/

In vivo activity:

Autoradiographic studies revealed a heterogeneous distribution of [125I]-iodophenpropitbinding sites in rat brain, with highest densities observed in specific cerebral cortical areas and layers,the caudate-putamen complex, the olfactory tubercles, the hippocampal formation, the amygdala complex, the hypothalamic area and the mammillary bodies. It is concluded that the histamine H3-receptor antagonist, [125I]-iodophenpropit, meets the criteria for a suitable radioligand for histamine H3-receptor binding studies in rat brain. Reference: Br J Pharmacol. 1994 Oct;113(2):355-62. https://pubmed.ncbi.nlm.nih.gov/7834183/

	Solvent	mg/mL	mM
Solubility
	DMSO	50.0	86.79
	Water	32.2	55.89

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 576.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Hansen KB, Mullasseril P, Dawit S, Kurtkaya NL, Yuan H, Vance KM, Orr AG, Kvist T, Ogden KK, Le P, Vellano KM, Lewis I, Kurtkaya S, Du Y, Qui M, Murphy TJ, Snyder JP, Bräuner-Osborne H, Traynelis SF. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. J Pharmacol Exp Ther. 2010 Jun;333(3):650-62. doi: 10.1124/jpet.110.166256. Epub 2010 Mar 2. PMID: 20197375; PMCID: PMC2879924. 2. Leurs R, Tulp MT, Menge WM, Adolfs MJ, Zuiderveld OP, Timmerman H. Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed. Br J Pharmacol. 1995 Oct;116(4):2315-21. doi: 10.1111/j.1476-5381.1995.tb15071.x. PMID: 8564266; PMCID: PMC1908963. 3. Rodrigues AA, Jansen FP, Leurs R, Timmerman H, Prell GD. Interaction of clozapine with the histamine H3 receptor in rat brain. Br J Pharmacol. 1995 Apr;114(8):1523-4. doi: 10.1111/j.1476-5381.1995.tb14934.x. PMID: 7541279; PMCID: PMC1510403. 4. Jansen FP, Wu TS, Voss HP, Steinbusch HW, Vollinga RC, Rademaker B, Bast A, Timmerman H. Characterization of the binding of the first selective radiolabelled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain. Br J Pharmacol. 1994 Oct;113(2):355-62. doi: 10.1111/j.1476-5381.1994.tb16995.x. PMID: 7834183; PMCID: PMC1510107.

In vitro protocol:

In vivo protocol:

1. Rodrigues AA, Jansen FP, Leurs R, Timmerman H, Prell GD. Interaction of clozapine with the histamine H3 receptor in rat brain. Br J Pharmacol. 1995 Apr;114(8):1523-4. doi: 10.1111/j.1476-5381.1995.tb14934.x. PMID: 7541279; PMCID: PMC1510403. 2. Jansen FP, Wu TS, Voss HP, Steinbusch HW, Vollinga RC, Rademaker B, Bast A, Timmerman H. Characterization of the binding of the first selective radiolabelled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain. Br J Pharmacol. 1994 Oct;113(2):355-62. doi: 10.1111/j.1476-5381.1994.tb16995.x. PMID: 7834183; PMCID: PMC1510107.